Janssen
Last updated Jun 16, 2026
Evidence Sources
3
Competitive Findings
0
Portfolio Developments
0
Regulatory Precedents
8
Clinical Programs
0
Confidence Coverage
69%
Audit
- Competitor findings: 0
- Portfolio developments: 0
- Self-competition findings removed: 0
- Unknown ownership findings removed: 0
Executive Summary
Material intelligence activity detected across:
- Diabetes
- SGLT2 Inhibitor
- Oncology
- Monoclonal Antibody
- Immunology
Highest priority development: Notice: Register of authorised online sellers of medicines in Northern Ireland
Regulatory precedent
Why this matters: illustrates how regulators handled a comparable approval decision relevant to Janssen.
Competitive pressure: Low
Portfolio impact: High
Evidence coverage: 69%
Active Signals
36
Investigate Priority
2
Opportunity Score
5407
Buyer Quality
6 · Emerging
Recent Signals
Latest intelligence events linked to this organization.
- EscalateJun 16, 2026Score 160Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis
Neurology · Alzheimer's Disease
- InvestigateJun 20, 2026Score 155FDA Approves OTC Naloxone Nasal Spray Rextovy for Opioid Overdose
Neurology · Opioid Overdose
- MonitorJul 7, 2026Score 152Janssen's Amivantamab Study in Advanced NSCLC Evaluates Safety and Efficacy
Oncology · NSCLC
Related Assets
Portfolio asset pages with evidence-based assessments.
No linked asset pages are available yet.
Portfolio Development
Owned-asset pipeline events — Phase III readouts, approvals, label expansions, and deals. Not classified as competitive threats.
No portfolio development items are linked to this company yet.
Competitive Intelligence Findings
Competitiva findings with evidence, reasoning, and confidence calibration.
No Competitiva findings are linked to this company yet.
Regulatory Developments
Regunera precedents with source attribution and confidence disclosure.
- Notice: Register of authorised online sellers of medicines in Northern IrelandModerate Confidence · 83%
Regulatory precedent may inform portfolio positioning
Sources (3)MHRAMHRARegunera - Research: Use of UK plasma for the manufacture of five further plasma derived medicinal products and vCJD riskLow Confidence · 54%
Regulatory precedent may inform portfolio positioning
Sources (3)MHRAMHRARegunera - FDA AP — CANAGLIFLOZIN (ORIG)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — SPORANOX (SUPPL)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera
Clinical Developments
Pipeline activity with auditable evidence and uncertainty disclosure.
No clinical developments are linked yet.
Capital Markets
SEC filings, IPO activity, and capital markets events from the Business Intelligence Layer.
No capital markets intelligence is available yet.
Financing History
Venture funding, follow-on offerings, PIPE financings, and debt financing.
No financing history is available yet.
Licensing & Partnerships
Licensing agreements, strategic partnerships, and distribution deals.
No licensing or partnership activity is available yet.
M&A Activity
Acquisitions, mergers, and divestitures.
No M&A activity is available yet.
Investor Activity
Earnings releases, investor presentations, and conference appearances.
No investor activity is available yet.
Executive Changes
CEO appointments, board changes, and leadership restructuring.
No executive changes are available yet.
Business Timeline
Chronological business intelligence events across financing, licensing, M&A, and commercial strategy.
No business timeline events are available yet.
Strategic Signals
Higher-order strategic intelligence fused from regulatory, scientific, business, and competitive events. Signals answer what it means — not just what happened.
Strategic signals will appear once sufficient event convergence is detected.
Investigate-Priority Items
Signals flagged for investigation or escalation — highest urgency for portfolio review.
- EscalateScore 160Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis
Neurology · Alzheimer's Disease
- InvestigateScore 155FDA Approves OTC Naloxone Nasal Spray Rextovy for Opioid Overdose
Neurology · Opioid Overdose
Humanexa Agent Questions
Suggested prompts to explore this organization's intelligence profile. Open a linked signal to ask the agent.
- What are the most material competitive threats to Janssen right now?
- Which regulatory precedents should Janssen monitor in Diabetes and SGLT2 Inhibitor?
- Which pipeline programs should Janssen prioritize for competitive review?
- What signals require immediate investigation for Janssen?
- Summarize the strategic implications of recent developments for Janssen.
- Where is the greatest uncertainty in Janssen's competitive positioning?